Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ravulizumab in severe COVID-19 pneumonia/ARDS
NCT04369469Phase 3Terminated
- Sponsor
- Alexion Pharmaceuticals
- Start
- May 2020
- Primary completion
- Feb 2021
- Modality
- Monoclonal Antibodies
- Countries
- 5
01
Overview
A Phase 3 trial of ravulizumab in COVID-19 pneumonia, acute respiratory distress syndrome (ARDS), sponsored by Alexion Pharmaceuticals. Started May 2020; status: terminated.
02
Drugs
ravulizumab
03
Conditions
COVID-19 pneumoniaacute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on NCT04369469.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04369469.